Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 7, 2016, Pages 1031-1038

  Spain, Lavinia ^a   Julve, Maximilian ^a   Larkin, James ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

advanced melanoma; BRAF mutation; Dabrafenib; MAPK pathway; toxicity; trametinib

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ALOPECIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHILL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERKERATOSIS; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; GENETICS; MUTATION; SKIN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEVER; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; NAUSEA; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS;

EID: 84963569025     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1168805     Document Type: Review

References (48)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417 (6892): 949-54.
2. Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015; 161 (7): 1681-1696.
3. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2012; 30 (20): 2522-2529.
4. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116 (6): 855-867.
5. Genome MC. BRAF V600E mutation in melanoma. [ cited 2015 Nov 21[; Available from: http://www.mycancergenome.org/content/disease/melanoma/braf/111/
6. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363 (9): 809-819.
7. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379 (9829): 1893-1901.
8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364 (26): 2507-2516.
9. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openLabel, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358-365.
10. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468 (7326): 973-977.
11. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2013; 31 (14): 1767-1774.
12. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008; 68 (12): 4853-4861.
13. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468 (7326): 968-972.
14. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480 (7377): 387-390.
15. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367 (2): 107-114.
16. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.
17. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371 (20): 1877-88.
18. Atkinson V, Larkin J, McArthur G, et al. Improved overall survival with cobimetinib (COBI) and vemurafenib (VEM) in advanced BRAFV600-mutated melanoma and biomarker correlates of efficacy. Society for Melanoma Research. San Francisco: Pigment Cell & Melanoma Research. Abstract; 2015.
19. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2015;33(17):1889-1895.
20. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372 (26): 2521-32.
21. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373 (1): 23-34.
22. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372 (1): 30-39.
23. Parakh S, Murphy C, Lau D, et al. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. J Clin Pharm Ther. 2015; 40 (1): 121-123.
24. GlaskoSmithKline. Product Monograph-Tafinlar (dabrafenib). Mar 2015 [ cited 2015 Nov 21[; Available from: http://www.gsk.ca/english/docs-pdf/product-monographs/tafinlar.pdf
25. GlaskoSmithKline. Product Monograph-Mekinist (trametinib). Apr 2015 [ cited 2015 Nov 21[; Available from: http://www.gsk.ca/english/docs-pdf/product-monographs/mekinist.pdf
26. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467 (7315): 596-599.
27. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366 (3): 207-215.
28. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res: Offi J Am Assoc Cancer Res. 2011; 17 (5): 989-1000.
29. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006; 439 (7074): 358-362.
30. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367 (18): 1694-703.
31. Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol: Off J Am Soc Clin Oncol. 2014; 32 (33): 3697-3704.
32. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363 (8): 711-723.
33. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372 (4): 320-330.
34. Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, openLabel, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as firstLine therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Cancer Congress (ECC); 2015;Vienna. Eur J Cancer. 2015;(Supp 3).
35. Long GV, Grob J-J, Davies M, et al. Baseline and postbaseline characteristics associated with treatment benefit across dabrafenib and trametinib registration pooled data. Society Melanoma Research (SMR). San Francisco: Pigment Cell & Melanoma Research. Abstract; 2015.
36. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371 (20): 1867-1876.
37. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, openLabel, phase 2 trial. Lancet Oncol. 2012; 13 (11): 1087-1095.
38. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015; 7 (2): 122-136.
39. Andrews MC, Behren A, Chionh F, et al. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol: Off J Am Soc Clin Oncol. 2013; 31 (35): e448-51.
40. Carlino MS, Kwan V, Miller DK, et al. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2015; 33 (11): e52-6.
41. Daud A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO; 2015; Chicago, US. J Clin Oncol. 2015.
42. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol: Off J Am Soc Clin Oncol. 2014; 32 (10): 1020-1030.
43. Sznol M, Kluger H, Callahan M, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO. J Clin Oncol. 2014; 32 (5s):(suppl; abstr LBA9003); 2014; Chicago; 2014.
44. Menzies AM, Ashworth MT, Swann S, et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2015; 26 (2): 415-421.
45. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). European Cancer Congress; 2015; Vienna. Eur J Cancer. 2015; 51 (Supp S3).
46. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18 (6): 683-695.
47. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013; 494 (7436): 251-255.
48. Turajlic S, Furney SJ, Stamp G, et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2014; 25 (5): 959-967.